Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Dehaier Medical Announces $20 Million Investment from Hangzhou Liaison

publication date: Apr 29, 2016
Dehaier Medical Systems of Beijing raised $20 million from Hangzhou Liaison Interactive Information Technology to support its wearable medical device and mobile medical businesses. In 2015, Dehaier had a difficult year as it restructured away from manufacturing and distributing in-licensed medical devices. The company reported a loss of $36 million on $6.6 million of revenues. In the future, Dehaier will focus on its wearable treatments for sleep apnea. For its part, Liaison will expand its internet products and services business to include smart medical devices and apnea products. More details....

Stock Symbol: (NSDQ: DHRM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital